Real-World Experience of Adalimumab in the Treatment of Hidradenitis Suppurativa

Published: 7 December 2020| Version 1 | DOI: 10.17632/pfz95dbvgm.1
Contributors:
,
Alyce Anderson,
Caroline Kettering,
Alicia Mizes,
Timothy Patton

Description

Supplemental Data on Reasons for Adalimumab Treatment Discontinuation and Secondary Treatment Initiated After Adalimumab Treatment Failure

Files

Institutions

University of Pittsburgh Medical Center

Categories

Hidradenitis Suppurativa

License